Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using high-dose isoniazid in MDR TB treatment because of suboptimal effect and toxicity concerns.
Authors
- Thomas Nordahl Petersen (ORCID: https://orcid.org/0000-0002-2484-5716)
- F. Morel (ORCID: https://orcid.org/0000-0003-0848-1198)
- Valentina Gerussi (ORCID: https://orcid.org/0000-0003-4527-2758)
- Lorenzo Guglielmetti (ORCID: https://orcid.org/0000-0003-0886-9635)
- Nicolas Véziris (ORCID: https://orcid.org/0000-0001-5660-6544)
- Esther Gydé (ORCID: https://orcid.org/0000-0002-6187-2326)
- Marwa Bachir (ORCID: https://orcid.org/0000-0001-6604-9964)
- D. Vallois (ORCID: https://orcid.org/0000-0001-9600-2569)
- Isabelle Bonnet (ORCID: https://orcid.org/0000-0002-4569-147X)
- Corentin Poignon (ORCID: https://orcid.org/0009-0008-0357-5834)
- J. Robert (ORCID: https://orcid.org/0000-0002-9380-0570)
- Alexandra Aubry (ORCID: https://orcid.org/0000-0003-4230-4793)
- Brigitte Rached
- Christophe Rioux
- Valérie Pourcher (ORCID: https://orcid.org/0000-0002-3879-1480)
Publication Details
- Journal
- Emerging infectious diseases
- Published
- 2025-02-21
- DOI
- https://doi.org/10.3201/eid3103.241473
- Citations
- 5
- Primary Topic
- Drug-Induced Hepatotoxicity and Protection
- Type
- article
- Field-Weighted Citation Impact
- 7.79